Trastuzumab deruxtecan (DS‐8201, known as dequdacimab), a HER2‐targeted ADC, has shown significant clinical efficacy in patients with lung cancer who harbor HER2 gene alterations. Here, ERBB2 is linked to lung carcinoma.